Projects funded by the NCN
Molecular mechanisms linking BRAF mutations and the expression of immunoregulatory molecules, galectin-1 and PD-L1 in melanoma
2014/15/N/NZ5/03662
Keywords:
melanoma BRAF mutation Ras pathway AP1 transcription factor galectin-1 PD-L1
Descriptors:
- NZ5_3: Pathogenesis of human diseases
- NZ5_7: Human disease treatment
- NZ5_5: Diagnostics in human diseases
Panel:
NZ5 - Human and animal noninfectious diseases: etiology, mechanisms, diagnosis and treatment of diseases, poisonings and injuries (without neurological diseases)
Host institution :
Instytut Hematologii i Transfuzjologii
woj. mazowieckie
Principal investigator (from the host institution):
Number of co-investigators in the project: 2
Call: PRELUDIUM 8 - announced on 2014-09-15
Amount awarded: 100 000 PLN
Project start date (Y-m-d): 2015-10-01
Project end date (Y-m-d): 2017-12-31
Project duration:: 27 months (the same as in the proposal)
Project status: Project settled
Information in the final report
- Publication in academic press/journals (1)
- Articles in post-conference publications (1)
- BRAF inhibition curtails IFN-gamma-inducible PD-L1 expression and upregulates the immunoregulatory protein galectin-1 in melanoma cellsAuthors:Patryk Gorniak, Maja Wasylecka-Juszczynska, Iwona Ługowska, Piotr Rutkowski, Anna Polak, Maciej Szydłowski, Przemysław JuszczynskiAcademic press:Molecular Oncology (rok: 2020, tom: Early view, strony: 45307), Wydawca: WileyStatus:PublishedDOI:10.1002/1878-0261.12695 - link to the publication
- BRAF V600E mutation in melanoma sustains IFN-gamma inducible PD-L1 expression by coactivating STAT1 and increasing protein translation.Authors:M. Wasylecka-Juszczyńska, P. Górniak, M. Szydłowski, A. Polak, P. JuszczyńskiConference:2018 ESMO Annual Meeting (rok: 2018, ), Wydawca: ElsevierData:konferencja 19-23 October 2018 Munich, Germany.Status:Published